HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Burkitt lymphoma — Clinical Guidelines

Overview

Burkitt lymphoma is a rare, aggressive subtype of non-Hodgkin lymphoma, accounting for less than 5% of adult lymphomas. It is characterized by rapid progression and high incidence of central nervous system (CNS) involvement and tumor lysis syndrome, especially in patients with high tumor burden 1.

Diagnosis

Clinical Presentation: Rapidly enlarging lymph nodes, abdominal masses, and symptoms related to organ involvement 1 6 7.

Imaging: CT scans and MRI for assessing extent of disease and CNS involvement 1.

Biopsy: Essential for definitive diagnosis; histopathology and immunohistochemistry confirm the diagnosis 1.

CNS Evaluation: Lumbar puncture and cerebrospinal fluid analysis to assess for CNS involvement 1.

Laboratory Tests: Complete blood count often shows marked anemia and thrombocytopenia 13.

Tumor Burden Assessment: Important for risk stratification and management decisions 1.

Management

First-Line Treatment: Dose-dense chemotherapy regimens, often incorporating protocols like CODOX-M/IVAC or variants 1 4.

CNS Prophylaxis: Intrathecal chemotherapy or high-dose systemic methotrexate to prevent CNS relapse 1.

Tumor Lysis Syndrome Prevention: Aggressive hydration, allopurinol, and monitoring electrolytes 1.

Supportive Care: Management of infections, anemia, and other complications; transfusion support as needed 1.

Radiation Therapy: Used for localized disease or bulky disease to improve local control 12.

Consolidation/Maintenance Therapy: Consideration based on risk stratification and institutional protocols 4.

Special Populations

Pediatrics: Similar aggressive treatment approaches as adults but with careful consideration of developmental impacts 6.

Comorbidities: Management tailored to address concurrent conditions like severe anemia or sepsis 7 13.

Developing Countries: Challenges in sustainability and access to intensive chemotherapy regimens noted 10.

Key Recommendations

Use Dose-Dense Chemotherapy Regimens for optimal outcomes in adult Burkitt lymphoma patients (Evidence: Strong 1 4).

Implement CNS Prophylaxis to reduce risk of central nervous system relapse (Evidence: Strong 1).

Monitor and Manage Tumor Lysis Syndrome Proactively to prevent life-threatening complications (Evidence: Moderate 1).

Consider Individualized Risk Stratification for treatment intensity and supportive care needs (Evidence: Moderate 2).

Integrate Palliative and Psychosocial Support for comprehensive care, especially in complex cases (Evidence: Expert opinion 3).

References

1 Ribrag V, Bron D, Rymkiewicz G, Hoelzer D, Jørgensen J, de Armas-Castellano A et al.. Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet. The Lancet. Haematology 2025. link00351-X) 2 de Armas-Castellano A, Infante-Ventura D, Del Pino-Sedeño T, Hernández YG, Quiros R, León-Salas B et al.. Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review. Cancer medicine 2025. link 3 Glinzak L, Palmer M, Portz JD, Dixon-Anderson A, Campbell D, Youngwerth J et al.. Art Therapy and Narrative Therapy Interventions for Pain Management: A Case Study with a Post-Quadruple Amputation Oncology Patient. Journal of palliative medicine 2025. link 4 Della Rocca AM, Leonart LP, Ferreira VL, Tonin FS, Steffenello-Durigon G, Del Moral JAG et al.. Chemotherapy Treatments for Burkitt Lymphoma: Systematic Review of Interventional Studies. Clinical lymphoma, myeloma & leukemia 2021. link 5 Roschewski M. The balancing act in Burkitt lymphoma. Blood 2021. link 6 Goel AN, Filimonov A, Teruya-Feldstein J, Salib C, Rousso JJ, Hackett AM et al.. Burkitt lymphoma of the nasopharynx causing life-threatening airway obstruction: A case report. American journal of otolaryngology 2021. link 7 Gravos A, Sakellaridis K, Tselioti P, Katsifa K, Grammatikopoulou V, Nodarou A et al.. Burkitt lymphoma of the ovaries mimicking sepsis: a case report and review of the literature. Journal of medical case reports 2018. link 8 . Study Probes Burkitt Lymphoma-Malaria Link. Cancer discovery 2015. link 9 Bilodeau E, Galambos C, Yeung A, Potluri A, Collins B. Sporadic Burkitt lymphoma of the jaw: case report and review of the literature. Quintessence international (Berlin, Germany : 1985) 2012. link 10 Earley A. Sustainability not all that matters: lessons from Cameroon. Archives of disease in childhood 2010. link 11 Coakley D. Denis Burkitt and his contribution to haematology/oncology. British journal of haematology 2006. link 12 Lanesky JR, Law DW, Roth SJ, Wadle RW. Burkitt lymphoma metastatic to penis. Urology 1980. link90381-7) 13 Durodola JI. Pattern of hemoglobin concentration in untreated Burkitt lymphoma patients in Ibadan. Journal of the National Medical Association 1979. link 14 Pardoe GI, Uhlenbruck G, Bird GW. Studies on some heterophile receptors of the Burkitt EB2 lymphoma cell. Immunology 1970. link

Burkitt lymphoma